>> No. >> No.
>> Not really.
No, don't see anything that's a tricyclic.
So then you have to make a decision,
am I done or am I not done?
And is this good enough if it doesn't include tricyclics, what do you think?
Should we keep reading?
>> I think we should keep reading.
>> Yeah, we spent all this time and got beta blockers and
we've got topiramate in there, so that seems to be reasonable.
Great, so let's look at the results of this table because it really does look
like we've got the two lines that we're interested in.
So here's the relative risk, you can see that the relative risk is two for
both of them.
>> Okay.
>> Now, a relative risk of two doesn't mean a relative risk increase.
It means that the number of people who are going to have a reduction in frequency by
50% is double in those who are on the drug versus placebo.
So two is actually a good thing.
Sometimes you gotta think about relative risk if it's a bad thing if it's higher,
but in this case it's a good thing.
But it's the same for both topiramate and beta blockers.
If you look at the absolute risk difference, this is the exact subtraction
of the risk of one versus the risk of another, that is pretty similar as well.
29%, in topiramate 22% in beta blocker.
Remember, they're comparing the drug versus placebo in both of those.
>> Okay.
>> So then we get to the million dollar question,
what is the number needed to treat?
And in other words, how many people do you need to put on a beta blocker or
topiramate in order to reduce their frequency by 50% of having migraines.
And so what is that number for topiramate and beta blocker, what do you see here?
>> Three versus four.
>> Three versus four, so
what does that sound like to you, good number, bad number?
>> Sounds like a pretty reasonable number based on some of the other numbers I've
seen for other agents.
>> Yeah, good.
So yeah, three and four are pretty low numbers.
You want to low number, you want to be able to treat a low
number of people in order to prevent one patient from having or
at least have one patient number reduction than the frequency of their migraines.
And if you look at the confidence interval,
that's three to six on topiramate, three to seven on beta blockers.
If you just compare those two, do they seem similar to each other or
different to each other?
Three versus four.
>> Pretty similar.
>> And why would you say that?
